



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

**Datasheet for 013-0105****Sheep IgG Fab****Overview**

<b>Description:</b>	Sheep IgG Fab Fragment - 013-0105
<b>Item No.:</b>	013-0105
<b>Size:</b>	2 mg
<b>Applications:</b>	IF, LFA, Other
<b>Origin:</b>	Sheep

**Product Details**

<b>Background:</b>	Sheep IgG Fab Fragment - secreted as part of the adaptive immune response by plasma B cells, immunoglobulin G constitutes 75% of serum immunoglobulins. Immunoglobulin G binds to viruses, bacteria, as well as fungi and facilitates their destruction or neutralization via agglutination (and thereby immobilizing them), activation of the compliment cascade, and opsonization for phagocytosis. The F(ab) fragment is the portion of the antibody that binds to the antigen target. The immunoglobulin Fab also possesses one constant and one variable region of both the heavy and light chain.
<b>Synonyms:</b>	Sheep IgG Fab fragment
<b>Species of Origin:</b>	Sheep
<b>Format:</b>	IgG Fab
<b>Type:</b>	Native Protein

**Target Details**

<b>Purity/Specificity:</b>	This product was prepared from normal serum by a multi-step process which includes delipidation, salt fractionation and ion exchange chromatography followed by papain digestion and extensive dialysis against the buffer stated above. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Sheep Serum, anti-Sheep IgG and anti-Sheep IgG F(ab') <sub>2</sub> . No reaction was observed against anti-Sheep IgG F(c) or anti- Papain.
----------------------------	---

**Application Details**

<b>Suggested Applications:</b>	IF, LFA, Other (Based on references)
<b>Application Note:</b>	Sheep IgG Fab fragment reagents are ideal for ELISA, western blotting, lateral flow, Immunohistochemistry, as well as other antibody detection methods.
<b>Assay Dilutions:</b>	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.


## Formulation

<b>Physical State:</b>	Liquid (sterile filtered)
<b>Concentration:</b>	2.0 mg/mL by UV absorbance at 280 nm
<b>Buffer:</b>	0.01 M Sodium Phosphate, 0.15 M Sodium Chloride, pH 7.2
<b>Preservative:</b>	0.01% (w/v) Sodium Azide
<b>Stabilizer:</b>	None

## Shipping & Handling


<b>Shipping Condition:</b>	Wet Ice
<b>Storage Condition:</b>	Store vial at 4° C prior to opening. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use. For extended storage, aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing.
<b>Expiration:</b>	Expiration date is one (1) year from date of receipt.

## Images



### Immunofluorescence Microscopy

Immunofluorescent analysis for death-inducing ligands and their receptors in splens from HIV-1-infected hu-PBL-NOD-SCID mice. (d) Triple staining for human CD4 (FITC, green), TUNEL (TRITC, red), and TRAIL (Cy5, blue) (magnification  $\times 100$ ). Merging of green and blue is shown as light blue. Merging of green and red is shown as orange. (e) High magnification ( $\times 500$ ) of d showing a TUNEL+CD4+ T cell conjugated with a TRAIL+CD4+ T cell (blue). Light blue indicates merging of green and blue. (f) Triple immunostaining for human CD3 (FITC, green), TUNEL (TRITC, red), and TRAIL (Cy5, blue) (magnification  $\times 200$ ). Merging of green and blue is shown as light blue. Merging of green and red is shown as orange. Sheep IgG Fab fragment (p/n 013-0105). Fig 2. PMID: 11238596.



### ELISA

Removal of EOLC causes nociception. (A) Rats were treated with i.p. DigiFab or Fab (p/n 013-0105) and their mechanical aversive threshold determined using the von-Frey method hourly over 4 hours. Means (SEM) displayed, n = 8-12 rats per group. (B-F): Rats were treated with i.c.v. DigiFab or Fab control. (B) The aversive threshold response to von Frey hairs is displayed as an average of both hindpaws before and for 4 hours after i.c.v. pre-treatment with Fab control or DigiFab. Means (SEM) displayed, n = 4 rats per group. (C) The eyelid closure response was measured before and hourly for 4 hours after pre-treatment with DigiFab or Fab control. Fig 2. PMID: 31173612.

## References

- Bian L et al. Rapid monitoring of vancomycin concentration in serum using europium (Eu) chelate nanoparticle-based lateral flow immunoassay. *Front Chem.* (2021)
- Gross, NB et al. Endogenous Na<sup>+</sup>, K<sup>+</sup>-ATPase inhibitors and CSF [Na<sup>+</sup>] contribute to migraine formation. *PLoS One* (2019)
- Miura, Y. et al. Critical contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to apoptosis of human CD4<sup>+</sup> T cells in HIV-1-infected hu-PBL-NOD-SCID mice. *The Journal of Experimental Medicine* (2001)

## Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.